CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Since PIK-III is not suitable for in vivo treatment [20], to examine the effect on engraftment of primitive LSCs, CD34+ CML cells were treated for 48 h with PIK-III, nilotinib or the combination, and transplanted into NSG mice with the engraftment of human Ph+ cells measured after 16 weeks.